Additional Relevant Details "Concert initiated a Phase 1 trial to evaluate the bioavailability and pharmacokinetics of CTP-656 under fed and fasted conditions in healthy volunteers."  CTP-656 is being developed for the treatment of cystic fibrosis and gating mutations.  The study is projected to complete in Q2 of 2016.